Catalyst Pharmaceuticals (CPRX) Assets Average (2011 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Assets Average came in at $1.1 billion in Q1 2026, up 27.91% YoY from $880.1 million in Q1 2025, and up 4.45% on a QoQ basis from $1.1 billion in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Assets Average (2011 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 16 years of Assets Average data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Assets Average rose 27.91% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 27.91% YoY) and the FY2025 annual result came in at $977.7 million, up 47.96% from the prior year.
- Assets Average grew to $1.1 billion in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2026 to a low of $242.4 million in Q1 2022.
- A 5-year average of $627.2 million and a median of $558.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average climbed 24.43% — and 2024, when it surged 83.79%.
- Tracing CPRX's Assets Average over 5 years: stood at $354.4 million in 2022, then gained by 24.63% to $441.7 million in 2023, then soared by 83.79% to $811.7 million in 2024, then surged by 32.78% to $1.1 billion in 2025, then advanced by 4.45% to $1.1 billion in 2026.
- The last three Assets Average figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 1.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Bn |
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 940.39 Mn |
| Mar 31, 2025 | 880.14 Mn |
| Dec 31, 2024 | 811.71 Mn |
| Sep 30, 2024 | 739.19 Mn |
| Jun 30, 2024 | 676.52 Mn |
| Mar 31, 2024 | 558.40 Mn |
| Dec 31, 2023 | 441.66 Mn |
| Sep 30, 2023 | 428.55 Mn |
| Jun 30, 2023 | 425.56 Mn |
| Mar 31, 2023 | 391.43 Mn |
| Dec 31, 2022 | 354.37 Mn |
| Sep 30, 2022 | 300.21 Mn |
| Jun 30, 2022 | 257.14 Mn |
| Mar 31, 2022 | 242.38 Mn |
| Dec 31, 2021 | 230.52 Mn |
| Sep 30, 2021 | 216.19 Mn |
| Jun 30, 2021 | 203.17 Mn |